Who
Alessandro Riva
Director
Company insider
Files Form 4 as: Director, BeOne Medicines; Director, Century Therapeutics; Director, Bicycle Therapeutics.
In numbers
- Trades disclosed
- 26
- Buys
- 0
- Sells
- 1
- Bought
- $0
- Sold
- $131K
- Companies
- 3
- Companies where not an officer
- 3
- First trade
- 17 Jun 2021
- Last trade
- 11 Jun 2026
- Last filed
- 15 Jun 2026
Companies traded
Activity over time
1 May – 1 Oct
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 11 Jun 2026filed 15 Jun 2026 | ONC BeOne MedicinesBiotechnology | SEC FORM 4 Code A | —18,980 at $0.00 | filing |
| 11 Jun 2026filed 15 Jun 2026 | ONC BeOne MedicinesBiotechnology | SEC FORM 4 Code A | —18,980 at $0.00 | filing |
| 11 Jun 2026filed 12 Jun 2026 | IPSC Century Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —74,000 at $0.00 | filing |
| 11 Jun 2026filed 12 Jun 2026 | IPSC Century Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —74,000 at $0.00 | filing |
| 22 May 2026filed 27 May 2026 | ONC BeOne MedicinesBiotechnology | SEC FORM 4 Sold | $66K212 at $309.51 | filing |
| 22 May 2026filed 27 May 2026 | ONC BeOne MedicinesBiotechnology | SEC FORM 4 Sold | $66K212 at $309.51 | filing |
| 2 Jan 2026filed 6 Jan 2026 | BCYC Bicycle TherapeuticsBiotechnology | SEC FORM 4 Code A | —7,380 at $0.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | BCYC Bicycle Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —14,761 at $0.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | BCYC Bicycle Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —14,761 at $0.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | BCYC Bicycle TherapeuticsBiotechnology | SEC FORM 4 Code A | —7,380 at $0.00 | filing |
| 12 Jun 2025filed 16 Jun 2025 | IPSC Century Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —44,000 at $0.00 | filing |
| 21 May 2025filed 22 May 2025 | ONC BeOne Medicinesoption or derivative · Biotechnology | SEC FORM 4 Code A | —22,750 at $0.00 | filing |
| 21 May 2025filed 22 May 2025 | ONC BeOne MedicinesBiotechnology | SEC FORM 4 Code A | —10,985 at $0.00 | filing |
| 25 Mar 2025filed 27 Mar 2025 | BCYC Bicycle Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —25,000 at $0.00 | filing |
| 25 Mar 2025filed 27 Mar 2025 | BCYC Bicycle TherapeuticsBiotechnology | SEC FORM 4 Code A | —12,500 at $0.00 | filing |
| 20 Jun 2024filed 21 Jun 2024 | IPSC Century Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —44,000 at $0.00 | filing |
| 5 Jun 2024filed 7 Jun 2024 | ONC BeOne Medicinesoption or derivative · Biotechnology | SEC FORM 4 Code A | —34,151 at $0.00 | filing |
| 5 Jun 2024filed 7 Jun 2024 | ONC BeOne MedicinesBiotechnology | SEC FORM 4 Code A | —16,341 at $0.00 | filing |
| 27 Jun 2023filed 29 Jun 2023 | IPSC Century Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —44,000 at $0.00 | filing |
| 15 Jun 2023filed 20 Jun 2023 | ONC BeOne Medicinesoption or derivative · Biotechnology | SEC FORM 4 Code A | —26,975 at $0.00 | filing |
News
BeOne Medicines (NASDAQ:ONC) Price Target Raised to $420.00ONC · tickerreport.com · 10 Oct 2026
0 headlines in the last 90 days name Alessandro Riva; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.